Frontier Medicines Closes $67 Million Series A, Will Focus on Chemoproteomics - BioSpace

Frontier Medicines Closes $67 Million Series A, Will Focus on Chemoproteomics  BioSpaceThe company will focus on chemoproteomics, which it calls a way of interrogating proteins in living systems. This allows them to identify potential new binding ...